Jim Kramer here to share with you a sample of my take on the market from today's

CNBC Investing Club warning meeting.

Well, look, healthcare as a sector, call it the struggles of UNH, some concerns about

pharma. Health care has been very disappointing this year.

Yes, it has.

Big surprise. I was a little bit more optimistic on health care coming into the year.

It hasn't worked out.

Even Eli Lilly, which had been doing so well, especially when we had the good pill data, just the other week, has now come all the way back down.

I'm really glad you mentioned Eli Lilly.

I've got Dr. Eric Topol on tonight, who's an incredible,

well-respected cardiologist, who's written some books.

And he has come out with an unqualified endorsement of the GLP-1.

He's on tonight, and I'm going to talk about it, for all sorts of things, far more than diabetes

and weight.

He even speculates maybe everybody has to take it.

So I think the people who are selling Eli Lilly are very misplaced about how much this drug is going to matter,

particularly because it really leapfrogged well over Nova Nordus.

So when I finished this book, when you read these books, they typically, people come on your show, people don't read the book. I read every page. And this book is in many ways. It's about how to live longer, how to stay young. GOP-1, probably the number one way. So you're interested in buying Lily down here? Yeah. Very much so.

People are selling it, they don't know what it is.

They're just saying it's another drug.

They're saying the government's cracking down.

But they don't realize this is worldwide.

...